ARCT today
$8.44+$0.00 (+0.00%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $17.96
Key levels
Resistance$12.44
Resistance$9.65
Support$8.05
Support$6.67
Latest news & SEC filings
AnalystRoth Capital Partners keeps Buy rating on Arcturus Therapeutics
EarningsArcturus Therapeutics posts Q3 2026 results, updates pipeline
EarningsArcturus Therapeutics holds Q3 2026 earnings call
EarningsArcturus Therapeutics posts smaller quarterly loss and higher revenue than expected
GuidanceArcturus sets 2027 timelines for ARCT-032 and ARCT-2601 programs
All ARCT news →About Arcturus Therapeutics
Arcturus Therapeutics develops RNA-based therapies for uncommon inherited liver and lung conditions. Its pipeline includes candidates for ornithine transcarbamylase deficiency and cystic fibrosis, plus a self-amplifying COVID-19 vaccine cleared in several countries. The company works with CSL Seqirus on shots against COVID-19, flu and other infections, and operates across the United States, Europe and Asia.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Arcturus Therapeutics Holdings Inc. (ARCT)
What Is the Price Target for ARCT?
SEPT Low Target
$19.00
SEPT Mid Target
$20.00
SEPT High Target
$20.00
Analyst Consensus
$20.00
Is ARCT a Buy or Sell Right Now?
Thesis
- •Revenue growing -46.1% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ARCT.
Start Free Trial →Is ARCT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$18.95
12
Moat Score
NONE
2/9
Piotroski Score
0.4
Altman Z-Score
What Is Smart Money Doing with ARCT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ARCT Growth Story
Revenue YoY
-46.1%
3yr Revenue CAGR
-26.4%
EPS Growth YoY
20%
FCF Growth YoY
-23.4%
Revenue Trend
DECLINING
Dark Pool Trades for ARCT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ARCT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:29:30 | $8.31 | 1,000 | $$8K | SELL |
| 15:17:15 | $8.28 | 1,392 | $$12K | SELL |
| 15:16:53 | $8.15 | 3,900 | $$32K | SELL |
| 15:13:47 | $8.25 | 1,212 | $$10K | BUY |
| 15:10:53 | $8.20 | 5,000 | $$41K | SELL |
5 dark pool trades shown · $$103K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About ARCT
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ARCT. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $ARCT (Arcturus Therapeutics Holdings Inc.) Price: $10.40 | Zone: $10.31 to $10.42 Conviction: HIGH Near resistance (82% of range) — breakout watch. Strong positive news (1+ vs 0-)
Join 3,500+ traders discussing ARCT in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Arcturus Therapeutics Holdings Inc. (ARCT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ARCT — frequently asked questions
What is ARCT stock price today?
Arcturus Therapeutics Holdings Inc. (ARCT) is at $8.44, up 0.00% (+$0.00) at the Nov 13, 2026 close.
Why is ARCT stock moving today?
Latest ARCT news — Nov 7, 2026: Roth Capital Partners keeps Buy rating on Arcturus Therapeutics · Nov 5, 2026: Arcturus Therapeutics posts Q3 2026 results, updates pipeline
What is the ARCT price target?
The average analyst price target for ARCT is $20.00, ranging from $19 to $20, based on 3 analysts. Latest: Leerink Partners maintains on Oct 9, 2026.
What do analysts rate ARCT?
Analyst ratings for ARCT: 1 Buy, 2 Hold, 0 Sell — consensus Hold.
Did ARCT beat earnings?
ARCT last reported on Aug 6, 2026: EPS -$0.84 vs -$1.00 expected — a beat of 15.7%.
Does ARCT pay a dividend?
ARCT does not currently pay a dividend.
What are ARCT support and resistance levels?
Support: $8.05, $6.67, $5.50. Resistance: $9.65, $12.44, $14.32.
What are insiders doing with ARCT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ARCT?
Nov 7, 2026: Roth Capital Partners keeps Buy rating on Arcturus Therapeutics · Nov 5, 2026: Arcturus Therapeutics posts Q3 2026 results, updates pipeline · Nov 5, 2026: Arcturus Therapeutics holds Q3 2026 earnings call